Physician profile
Rohit Krishna
NPI 1831197912
$57,317.02
in general payments reported to CMS, 2019-2025
13 companies · $16K in 2025
The $16K reported for 2025 was more than what 96% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $202 · 2020: $105 · 2021: $391 · 2022: $12K · 2023: $12K · 2024: $17K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Consulting Fee: $16K · Food and Beverage: $271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,333.32 |
| Consulting Fee | $16,333.33 |
| Food and Beverage | $270.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $40,060.67 | 2022-2025 | Stellaris, Envista Envy Iol |
| Glaukos Corporation | $16,462.76 | 2019-2025 | Istent Infinite, Travoprost Intraocular Implant - Idose |
| Carl Zeiss Meditec, INC. | $315.56 | 2019-2021 | |
| Carl Zeiss Meditec USA, INC. | $232.93 | 2021-2024 | Atlas 500, Iolmaster 700 |
| Horizon Therapeutics Plc | $60.32 | 2021 | |
| Abbvie INC. | $52.91 | 2025 | |
| Sun Pharmaceutical Industries INC. | $44.99 | 2019-2025 | |
| Alcon Vision LLC | $28.55 | 2025 | Clareon |
| Genentech USA, INC. | $19.52 | 2023 | Vabysmo |
| Novartis Pharmaceuticals Corporation | $16.77 | 2019 | |
| Coopervision INC. | $14.90 | 2022 | |
| The Cameron-Ehlen Group, INC. | $7.14 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohit Krishna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.